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Advanced glycation end products (AGEs) may induce cardiac remodeling in kidney disease by promoting ﬁbroblast growth factor
23 (FGF-23) expression. Since AGEs are increased in diabetes mellitus (DM), our ﬁrst aim was to evaluate the existence of any
potential association between AGEs, FGF-23, inﬂammation, and increased cardiovascular risk in DM patients on dialysis (CKD-
G5D). Secondarily, we explored the potential role of the soluble receptor for AGEs (sRAGE) as a marker of heart failure. Levels
of glycated albumin (GA), sRAGE, c-terminal FGF-23 (cFGF-23), brain natriuretic peptide (BNP), and inﬂammatory mediators
were compared between DM and non-DM CKD-G5D patients. The levels of sRAGE, cFGF-23, BNP, and proinﬂammatory
markers were over the ranges of normality in both DM and non-DM groups. Only GA and sRAGE levels were increased
in DM compared to non-DM patients. Plasma levels of sRAGE and CRP were the only independent predictors of BNP
concentration. In conclusion, in DM CKD-G5D patients, sRAGE appeared to be a marker of cardiac remodeling. Indeed, its
increase could be a potential protective mechanism against the increased risk of cardiovascular complications related to AGEs
and inﬂammation. The causal relationship between sRAGE and cardiovascular risk in these patients needs to be further
conﬁrmed by mechanistic studies.
1. Introduction
End-stage renal disease (ESRD) in patients with chronic kid-
ney disease (CKD) is a condition characterized by including
volume overload, hyperkalemia, metabolic acidosis, hyper-
tension, anemia, and mineral and bone disorders (MBDs),
and it is considered a clinical model of premature aging.
ESRD patients have an increased risk of diﬀerent diseases,
mainly at cardiovascular and cerebrovascular level, and have
a mortality rate at least 20–30 times higher than what their
healthy age-matched patients have [1]. ESRD is stricly related
to cardiovascular diseaes (CVDs) through several mecha-
nisms, which include the inﬂammatory response, the produc-
tion of reactive oxygen species, the phosphate toxicity, and
the activation of diﬀerent endocrine pathways, such as the
ﬁbroblast growth factor 23 system (FGF-23) [1]. Also, MBDs
represent a severe complication and an important mortality
risk factor in CKD patients on dialysis (CKD-G5D) [2].
FGF-23 is a 32 kDa glycoprotein secreted by osteocytes
which has been receiving great interest as a new risk factor
for CVDs and death both in individuals with CKD [3, 4]
and in adults with preserved kidney function [5, 6]. In
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particular, increased FGF-23 levels have been associated with
vascular dysfunction, left ventricular hypertrophy, and the
risk of heart failure, stroke, and death [3, 7, 8]. In CKD,
FGF-23 levels increase as a compensatory mechanism to keep
normal phosphate levels by inhibiting renal phosphate reab-
sorption and 1-alpha-hydroxilase activity, the key enzyme for
calcitriol production [9]. Anyway, although this increase is
acknowledged as a physiological protective mechanism, it
could directly contribute to the onset and progression of
inﬂammation and CVDs [7, 8, 10].
It has been recently observed that FGF-23 expression
may be promoted in vitro by advanced glycation end
products (AGEs) through the upregulation of NF-κB
[11]. Indeed, in a mouse model of renal failure, the activa-
tion of the cell-surface receptor for AGEs (RAGE) induced
FGF-23 expression in cardiac ﬁbroblasts and promoted
cardiac remodeling [12].
Metabolic disorders including diabetes mellitus (DM) are
characterized by high levels of AGEs that are key mediators
of DM-related complications, inﬂammation, and aging.
These products, generated by nonenzymatic reactions
between reducing sugars and protein or lipids, mainly pro-
mote reactive oxygen species generation and a proinﬂamma-
tory response through RAGE activation. Besides the cell
membrane form, RAGE also exists as a soluble circulating
molecule, sRAGE. This form, by binding the circulating
AGEs and preventing their activation of RAGE, plays a role
as an important protective agent [13, 14].
In renal diseases, AGEs and sRAGE may accumulate
due to their increased formation and reduced elimination
[15–19]. Indeed, the RAGE pathway has been suggested
as a causal risk factor for both atherosclerosis [20] and left
ventricular hypertrophy [21] in these patients.
Although the potential role of sRAGE as a marker for
CVDs has been pointed out in diﬀerent previous studies
[22–27], its role in ESRD is less characterized.
To better evaluate the role of the AGEs/sRAGE pathway
in ESRD, we ﬁrstly evaluated the existence of any potential
association between AGEs, FGF-23, inﬂammation, and
increased risk of CVDs in DM CKD-G5D patients. Second-
arily, we explored the potential role of sRAGE as a marker
of heart failure in CKD-G5D.
2. Materials and Methods
2.1. Source Population. We performed a cross-sectional
study in patients on CKD-G5D. We enrolled patients
who underwent hemodialysis (HD) or peritoneal dialysis
(PD) treatment for at least 3 months with age≥ 18 years
and agreement to participate in the study. We excluded
patients with missing or incomplete clinical history, inca-
pacity to cooperate to the study, and hepatic encephalopa-
thy. This study was performed in accordance with the
ethical principles of the Declaration of Helsinki, as revised
in 2013. The protocol was approved by the Ethics Com-
mittee of San Bortolo Hospital (N.41/14). All participants
were informed of the objectives of the study and signed
the informed consent.
2.2. Measurements
2.2.1. Data Collection. Demographic, anthropometric, and
clinical data (i.e., age, gender, smoking status, alcohol con-
sumption, hypertension, DM, cardiovascular disease, and
cerebrovascular disease) were collected. Screening and
diagnosis of DM were performed according to the American
Diabetes Association guidelines [28]. Hypertension was
deﬁned as values≥ 140mmHg systolic blood pressure and/
or ≥90mmHg diastolic blood pressure [29].
Blood samples in EDTA were collected during outpatient
visits in PD patients or prior to dialysis treatment after long
interdialytic intervals in HD patients. Samples for nonrou-
tine assays were immediately frozen and stored at −80°C until
measurements.
Concerning routine biochemical assays, total bilirubin
(reference value (RV): male 0.3–1.5mg/dL, female 0.2–
1.2mg/dL), calcium (RV: 8.5–10.5mg/dL), phosphorous
(RV: 2.2–4.2mg/dL), LDL cholesterol (RV: <115mg/dL),
HDL cholesterol (RV: male> 40mg/dL, female> 45mg/dL),
and total protein (RV: 6.4–8.7 g/dL) were quantiﬁed using
colorimetric methods on Dimension Vista® 1500 Intelligent
Lab System (Siemens, Milan, Italy). The same laboratory
equipment was used for urea (RV: 15–50mg/dL under
70 years old, 19–65mg/dL over 70 years old), creatinine
(RV: male up to 1.3mg/dL, female up to 0.9mg/dL under
70 years old and 1.2mg/dL over 70 years old), uric acid
(RV: male 3–8mg/dL, female 2.4–6.6mg/dL under 70 years
old and 3–8mg/dL over 70 years old), alanine aminotrans-
ferase (ALT) (RV: female< 31U/L, male< 53U/L under 70
years old and <34U/L over 70 years old), and aspartate
aminotransferase (AST) (RV: <37U/L), which were all
quantiﬁed by enzymatic methods, for total cholesterol
(RV: <190mg/dL) and triglycerides (RV: <150mg/dL), both
measured by kinetic enzyme assays, then for brain natriuretic
peptide (BNP) (RV: <50ng/L under 70 years old, <300ng/L
in the age range 51–75, and <600ng/L over 70 years old)
and C-reactive protein (CRP) (RV: <0.5mg/dL), which were
quantiﬁed by an immunochemiluminescent and a turbidi-
metric method, respectively. Sodium (RV: 35–145mmol/L),
potassium (3.3–5.0mmol/L), and chloride (95–110 mmol/L)
were measured on Dimension Vista System using ion-
selective electrodes. Glucose (RV: <100ng/mL) and albumin
(RV: 2.1–4.5 g/dL) were quantiﬁed on the ILab650 system
(Instrumentation Laboratory, A Werfen Company, Milan,
Italy) using an enzymatic and a colorimetric method, respec-
tively. Parathyroid hormone (intact PTH) (RV: 5–35 ng/L),
25-hydroxy vitamin D (25-(OH)D3) (RV: 30–100 μg/L),
and β2-microglobulin (β2-microglobulin: 0.8–2.5mg/L)
were measured using the Liaison XL system (DiaSorin,
Vercelli, Italy) by immunochemiluminescent methods. The
acid-base equilibrium (pH, HCO3
−) (RV: 7.32–7.42 for pH,
22–29mmol/L for HCO3
−) was quantiﬁed by the Rapidpoint
405 Blood Gas Analyzer (Siemens).
2.2.2. FGF-23 Quantiﬁcation. The carboxyl-terminal (C-
terminal) portion of FGF-23 (cFGF-23) levels was deter-
mined in plasma by two-site enzyme-linked immunosorbent
assay (ELISA), according to the manufacturer’s protocol
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(Immutopics Inc., San Clemente, CA). Two hundred micro-
liters of plasma was used to assay the sample in duplicate.
Samples with values greater than the highest standard were
diluted 1 : 10 or greater with the 0RU/mL standard or
optional sample diluent reagent and reassayed. The lowest
concentration of cFGF-23 measurable is 1.5 RU/mL, and
the maximum intra- and interassay coeﬃcients of variations
were 2.4% and 4.7%, respectively.
2.2.3. Glycated Albumin Quantiﬁcation. The glycated albu-
min (GA) and the percentage of glycated albumin (GA%)
were determined in plasma by the enzymatic QuantiLab®
glycated albumin assay (Instrumentation Laboratory) using
the ILab650 system (Instrumentation Laboratory). The ILab
analyzer automatically calculates the results of each sample.
The GA% is calculated by the GA/albumin ratio and cor-
rected by arithmetic algorithm deﬁned to align the GA%
levels to the HPLC method [30–32]. The minimum
detectable concentration of GA measurable is 1.15 g/L.
The maximum intra- and interassay coeﬃcient of variations
were 2.1% and 1.3% for GA and 1.2% and 1.0% for GA%,
respectively.
2.2.4. sRAGE and Inﬂammatory Cytokine Quantiﬁcation.
The quantitative determinations of sRAGE, pentraxin-3
(PTX3), and tumor necrosis factor alpha (TNFα) concentra-
tions were performed by commercial human ELISA kits
(R&D System, Minneapolis, MN, USA) according to the
manufacturer’s instructions. The minimum detectable dose
ranged from 1.23 to 16.14 pg/mL for sRAGE, 0.007 to
0.116 ng/mL for PTX3, and 0.5 to 5.5 pg/mL for TNFα. The
maximum intra- and interassay coeﬃcients of variations
were, respectively, 4.8% and 8.3% for sRAGE, 4.4% and
6.2% for PTX3, and 5.2% and 7.4% for TNFα. The
GloMax®-Multi Microplate Multimode Reader was used for
photometric measurements (Promega, Milan, Italy).
2.3. Statistical Analysis. Qualitative variables are summarized
as numbers and percentages; quantitative variables are
expressed as mean with standard deviation (SD) or median
and interquartile range (IQR). The normality of data distri-
bution was assessed by the Kolmogorov-Smirnoﬀ test. t-test
and Mann–Whitney U test were used for group comparison.
To test the univariate association between variables, Pearson
(for normal-distributed data) or Spearman (for non-normal
distributed data) correlation tests were used, as appropriate.
Stepwise regression analysis was performed to evaluate
the independent correlates of BNP in CKD-G5D patients.
All statistical analyses were performed using STATISTIX
7.0 (Analytical Software, Tallahassee, FL, USA) and
GraphPAd Prism 5.0 biochemical statistical package (Graph-
Pad Software, San Diego, CA, USA). A p value< 0.05 was
considered signiﬁcant.
3. Results
3.1. Patient Characteristics. We enrolled a total of 76 CKD-
G5D patients (32 HD, 44 PD, median age 62.41 (IQR:
52.02–72.05) years, 55M) of which 24 were with DM (type
2 DM: 22; type 1 DM: 2) (mean age 61.01 (50.94–72.83)
years, 35M) and 54 were without DM (65.42 (54.83–70.94)
years, 20M). Demographic and anthropometrical data are
presented in Table 1. Sixty-seven patients (87%) were under
treatment with vitamin D or its synthetic analog. The active
vitamin D therapy, which included cholecalciferol and calci-
triol, was used in 45 (59.21%) patients. Twenty-two (28.95%)
patients were treated with paricalcitol and cinacalcet.
Biochemical characteristics of patients included in the
study are shown in Table 2.
3.2. Plasma Levels of GA, FGF-23, sRAGE, and Inﬂammatory
Markers. CKD-G5D patients were classiﬁed according to the
presence of DM, and the two groups were compared to
explore potential diﬀerences in the levels of GA, as a marker
of protein glycation, sRAGE, cFGF-23, and the proinﬂamma-
tory molecules CRP, PTX-3, and TNFα.
According to the reference limits of GA [33], which
have been very recently documented also in Caucasians
Table 1: Demographic, anthropometric, and clinical characteristics of CKD patients included in the study.
All CKD (n = 76) Non-DM CKD (n = 52) DM CKD (n = 24) p
Age (years) 62.41 (52.02–72.05) 61.21± 13.94 65.42 (54.83–70.94) 0.80
Male gender (n, %) 55, 72.37% 35, 67.31% 20, 83.33% 0.18
BMI 27.20± 5.56 27.38± 5.28 24.14 (22.10–31.35) 0.50
HD (n, %) 32, 42.11% 20, 38.46% 12, 50% 0.45
Smoking (n, %) 9, 11.84% 4, 7.69% 5, 20.83% 0.13
Ex-smoking (n, %) 29, 38.16% 20, 38.46% 9, 37.50% 1.00
Alcohol consumption (n, %) 2, 2.63% 2, 3.85% 0, 0% 1.00
Hypertension (n, %) 48, 63.16% 35, 67.30% 13, 54.17% 0.31
Cardiovascular diseases (n, %) 22, 28.95% 12, 23.08% 10, 41.67% 0.11
Cerebrovascular diseases (n, %) 4, 5.26% 2, 3.85% 2, 8.33% 0.59
Therapy with activated vitamin D 45, 59.21% 31, 59.62% 14, 58.33% 1.00
Therapy with paricalcitol 22, 28.95% 17, 32.69% 5, 20.83% 0.05
Data are expressed as median (25th–75th percentiles) or number and proportions. BMI: body mass index; HD: hemodialysis. Comparison between groups was
performed by Mann–Whitney U test or Fisher exact test.
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[34, 35] (upper reference limit: 14.5% (95% CI: 14.3–14.7)
[34]; range: 9.0% (90% CI: 8.7–9.5) to 16.0% (90% CI:
15.6–16.4) [35]), in non-DM CKD-G5D patients, GA
(95% CI: 12.52–13.66) was within the ranges of normality
(Table 1 and Figure 1). Diﬀerently, in the DM CKD-G5D
group, it reached pathological levels and it was statistically
signiﬁcantly higher than in the non-DM CKD-G5D
patients (p < 0 001) (Table 1 and Figure 1). According to
our previous results on sRAGE concentrations in healthy
subjects (mean value 1363.0± 693.2 ng/mL) [36], sRAGE
levels were above the normal values both in non-DM CKD-
G5D and DM CKD-G5D patients and resulted statistically
signiﬁcantly higher in the DM CKD-G5D compared to
the non-DM CKD-G5D group (p < 0 05) (Table 1 and
Figure 1). cFGF-23 levels were higher than the reference
value (<180RU/mL), but we did not ﬁnd any signiﬁcant
diﬀerence between groups (non-DM CKD-G5D: median
value, 1345.00, 25th–75th percentiles (508.10–3087.00) RU/
mL; DM CKD-G5D: 1707.00, (1183.00–4016.00RU/mL)
(Table 2 and Figure 1)).
As markers of inﬂammation, we evaluated CRP, PTX-3,
and TNFα. According to the existing reference values for
healthy subjects (<0.5mg/L for CRP, <1.18 ng/mL for PTX-
3, and 1.12 pg/mL for TNFα, resp.), all the proinﬂammatory
markers evaluated were greatly upregulated in both groups
but without signiﬁcant diﬀerences between them (Table 2
and Figure 2).
A univariate association analysis was then performed
in CKD-G5D patients to explore potential correlations
between the markers previously studied. We did not ﬁnd any
signiﬁcant correlation between GA and cFGF-23 (r = 0 073,
p = 0 529), between sRAGE and cFGF-23 (r = −0 056;
Table 2: Biochemical characteristics of CKD-G5D patients included in the study.
All CKD-G5D (n = 76) Non-DM CKD-G5D (n = 52) DM CKD-G5D (n = 24) p
Creatinine (mg/dL) 9.40± 3.09 9.71± 3.39 8.71± 2.19 0.13
Uric acid (mg/dL) 5.70± 1.29 5.67± 1.24 5.76± 1.41 0.78
Urea (mg/dL) 124.60± 31.41 122.10± 31.60 129.90± 30.97 0.32
Total bilirubin (g/dL) 0.40 (0–30-0.50) 0.40 (0.30–0.50) 0.42± 0.16 0.56
pH venous 7.35 (7.32–7.38) 7.35 (7.32–7.38) 7.36 (7.33–7.38) 0.47
HCO3 venous (mmol/L) 25.18± 4.29 25.02± 4.54 25.53± 3.76 0.63
K—potassium (mmol/L) 4.46± 0.72 4.46± 0.71 4.48± 0.75 0.91
Na—sodium (mmol/L) 140.00 (138.00–142.00) 140.00 (138.30–142.80) 139.50± 3.02 0.33
Cl—chloride (mmol/L) 101.50 (97.00–105.00) 101.10± 4.28 101.20± 5.74 0.95
Ca—calcium (mg/dL) 8.95± 0.47 8.98± 0.48 8.88± 0.44 0.38
P—phosphorus (mg/dL) 5.15± 1.36 5.14± 1.34 5.20± 1.44 0.86
Total cholesterol (mg/dL) 157.10± 40.66 163.90± 35.42 142.50± 47.76 0.032
LDL cholesterol (mg/dL) 80.82± 35.92 85.65± 32.32 70.33± 43.17 0.016
HDL cholesterol (mg/dL) 44.00 (38.00–54.00) 45.50 (40.00–60.25) 42.42± 11.81 0.030
Triglycerides (mg/dL) 131.50 (86.25–201.80) 117.50 (82.75–204.30) 154.00± 74.15 0.55
ALT (UI/L) 19.00 (15.00–24.00) 20.12± 7.79 20.00 (15.25–31.25) 0.30
AST (UI/L) 11.00 (6.00–15.75) 11.00 (6.00–14.75) 11.42± 6.79 0.93
Glucose (mg/dL) 103.50 (92.00–138.50) 99.00 (91.00–110.00) 165.00 (131.80–220.80) <0.0001
Total protein (g/dL) 7.00± 0.57 7.02± 0.63 6.96± 0.41 0.64
Albumin (g/dL) 35.03± 4.82 35.01± 4.81 34.70 (31.35–39.23) 0.75
GA% 14.00 (12.03–17.15) 13.09± 2.05 18.30 (17.13–23.20) <0.0001
iPTH (pg/mL) 103.50 (53.25–211.00) 102.00 (55.00–254.30) 134.30± 119.90 0.46
25-(OH)D3 (ng/mL) 17.90 (10.93–23.28) 17.95 (11.45–25.15) 16.32± 6.77 0.30
CRP (mg/L) 0.34 (0.29–0.78) 0.31 (0.29–0.77) 0.41 (0.29–1.04) 0.39
β2-microglobulin (ng/mL) 22.80 (16.66–28.98) 22.96 (16.88–29.61) 21.08± 7.66 0.24
BNP (pg/mL) 2542.00 (1511.00–10762.00) 2265.00 (1108.00–8272.00) 3064.00 (1795.00–18558.00) 0.148
cFGF-23 (RU/mL) 1441.00 (759.00–3614.00) 1345.00 (508.10–3087.00) 1707.00 (1183.00–4016.00) 0.142
sRAGE (pg/mL) 3089.30± 1339.74 2838.00± 1163.75 3633.80± 1548.45 0.015
PTX3 (ng/mL) 1.57 (0.76–2.94) 1.57 (0.75–3.23) 1.89± 1.48 0.65
TNFα (pg/mL) 10.71 (4.85–21.34) 12.15 (5.60–24.19) 11.66± 10.28 0.134
Data are expressed as mean ± SD or median (25th–75th percentiles). ALT: alanine transaminase; AST: aspartate transaminase; BNP: brain natriuretic peptide;
CRP: C-reactive protein; GA: glycated albumin; cFGF-23: c-terminal portion of ﬁbroblast growth factor-23; iPTH: intact parathyroid hormone; 25-(OH)D3: 25-
hydroxy vitamin D; PTX3: pentraxin-related protein PTX3; sRAGE: soluble receptor for advanced glycation end products; TNFα: tumor necrosis factor alpha.
Comparison between groups was performed by unpaired t-test or Mann–Whitney U test. p values less than 0.05 are indicated in bold.
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p = 0 633), and then between GA and sRAGE (r = 0 29,
p = 0 061).
3.3. Relationships between CVD Risk Factors and BNP.
The potential correlations between BNP, a marker used
for screening and prognosis of heart failure, and clinical
variables in CKD-G5D patients were explored. BNP was
signiﬁcantly positively correlated with creatinine (r = 0 27;
p = 0 017), potassium (r = 0 247; p = 0 031), CRP (r = 0 260;
p = 0 023), sRAGE (r = 0 314; p = 0 006), and β2-microglob-
ulin (r = 0 407; p < 0 001) and signiﬁcantly negatively corre-
lated with sodium (r = −0 341; p = 0 003).
In a multivariate stepwise regression model, plasma
sRAGE and CRP levels were the only independent predictors
of BNP (Table 3). All the other parameters did not enter
the model.
4. Discussion
CKD-G5D patients are an interesting model of premature
aging. These patients, due to the lack of renal function, show
a uremic milieu in which phosphate retention and uremic
toxin accumulation, including AGEs, promote oxidative
stress and inﬂammation. These conditions may in turn acti-
vate speciﬁc cellular mechanisms, such as telomere attrition,
DNA damage, and mitochondrial dysfunction, which aﬀect
cellular homeostasis, promote premature cellular senescence,
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Figure 1: Evaluation of GA, FGF-23, and sRAGE levels in CKD-G5D patients. GA levels (a) and sRAGE (c) were higher in DM CKD-G5D
patients than in non-DM CKD-G5D patients (∗∗∗p < 0 001 and ∗p < 0 05, resp.). FGF-23 levels (b) were the same in the two groups.
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Figure 2: Evaluation of inﬂammation-related molecules in CKD-G5D patients. CKD-G5D patients were classiﬁed into two groups according
to the presence of diabetes mellitus (DM). CRP (a), PTX3 (b), and TNFα (c) levels were compared between DM and non-DM groups.
No statistically signiﬁcant diﬀerences were observed between the two groups.
Table 3: Stepwise regression analysis (t value) of the association between some independent variables and BNP in CKD-G5D patients.
BNP (pg/mL)
Independent variables
Model R2
CRP (mg/L) Creatinin (mg/dL) Na (mmol/L) K (mmol/L) sRAGE (pg/mL)
2.44 0.84 −0.81 1.40 2.72 0.20
p value 0.017 0.40 0.42 0.17 0.008
Constant value
Regression coeﬃcient 1652.06 2.49
SE regression coeﬃcient 676.00 0.92
CRP: C-reactive protein; sRAGE: soluble receptor of advanced glycation end products; SE: standard error.
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and increase the risk of death mainly due to cerebrovascular
and cardiovascular complications [37].
AGEs are recognized as important damaging molecules
for the cardiovascular system due to their ability to promote
endothelial dysfunction, arterial stiﬀness, atherosclerosis,
immune system alteration, and cardiac ﬁbrosis and remodel-
ing [38–41]. It is known that the generation of AGEs is
strongly increased in DM, being AGEs by-products of hyper-
glycemia. Recent preclinical studies [11, 12] suggested that
these molecules, in addition to their known role as proin-
ﬂammatory agents, are able to increase the production of
FGF-23, a key molecule involved in the crosstalk between
kidney function, bone metabolism, and the cardiovascular
system [7, 8, 42]. To our knowledge, this is the ﬁrst study
investigating in human any potential association between
AGEs, sRAGE, cFGF-23, and cardiovascular complications
in CKD-G5D patients with DM. Our results indicated that
both GA and sRAGE levels were increased in DM CKD-
G5D compared to non-DM CKD-G5D patients, but the
levels of cFGF-23 did not diﬀer between the two groups. Sim-
ilarly, the concentrations of the proinﬂammatory molecules
evaluated were almost the same in the two groups, although
we expected to observe higher levels in DM CKD-G5D
patients, as a consequence of the increased glycated milieu.
To our opinion, one possible explanation just deals with the
upregulation of sRAGE. Diﬀerent studies have shown that
sRAGE levels are increased in DM as a counteract system
against glycated products [26, 43–46]. Assuming the activa-
tion of the same mechanism also in our DM CKD-G5D
patients, sRAGE, by blocking glycated products, could
reduce the activation of various damaging cellular mecha-
nisms, including the stimulation of cFGF-23 and other pro-
inﬂammatory molecules. Indeed, since AGE accumulation
has been associated with the development and progression
of heart failure [47, 48], the lack of diﬀerence also in BNP
levels between the two groups reinforces the idea of a protec-
tive role of sRAGE in DM CKD-G5D patients. A further
explanation could arise by considering that cFGF-23, which
starts to rise early in CKD, in CKD-G5D is up to thousand-
fold higher than the normal levels [49]. For this reason, we
could not exclude the possibility that in DM CKD-G5D
patients, a further stimulation of the FGF-23 system by
potential activators, like AGEs [11, 12], is not possible or
may not be appreciated.
Concerning AGEs, we focused our attention on GA. As
for other AGEs, we expected to observe that GA levels were
over the ranges of normality not only in DM CKD-G5D
group but also in non-DM CKD-G5D patients, due to the
increased oxidative stress and the reduced kidney clearance
typical of the disease [15, 17, 18, 50]. Of course, the upregu-
lation of sRAGE at levels above controls in both groups and
its further increase in DM seem to suggest the existence of
a glycated milieu in all CKD-G5D patients, regardless of the
presence of DM. According to these data, the observation
that GA levels were over the range of normality only in DM
CKD-G5D group strongly reinforces the utility of GA as a
useful glycation marker for DM monitoring in CKD-G5D
patients in which HbA1c does not work well due to just
kidney-related anemia [51, 52].
sRAGE has been regarded as a diagnostic and prognostic
marker of cardiovascular outcome in various pathological
conditions, that is, obesity, DM, metabolic syndrome,
chronic heart failure, and also CKD [20–22, 24, 26]. Con-
cerning heart failure, conﬂicting results on the relationship
between sRAGE and heart failure risk exist. Both lower
and higher circulating levels of sRAGE were described as
valuable predictors of heart failure, its severity, and mortal-
ity, and some studies suggested the existence of a robust
association between NT-pro BNP levels, as a diagnostic
and prognostic marker of heart failure and sRAGE [27, 48,
53–56]. Also, in our study, we observed a positive correlation
between sRAGE and BNP. Indeed, sRAGE emerged as an
independent predictor of BNP levels, thus suggesting its
potential role as a marker of cardiac remodeling in CKD-
G5D patients.
Leonardis et al. [21] studied the relationships between
sRAGE and left ventricular hypertrophy in CKD, not in
CKD-G5D. They showed that sRAGE levels were increased
compared to those of controls but, unlike us, were inversely
correlated with functional parameters of cardiac function.
Probably, since the two studies have been performed on
diﬀerent populations, they are not easily comparable and
further studies in ESRD are therefore necessary to support
data herein presented.
The study of Kim et al. [20] has been performed on
PD patients but explored sRAGE correlation with carotid
atherosclerosis, not parameters of heart failure. Although
diﬀerent in its aim, some data of this study could be useful
for a better comprehension also of our results. They observed
that CKD-G5D patients had increased sRAGE levels com-
pared to controls but, diﬀerently from our results, the sub-
group of DM patients had lower sRAGE and higher IL-6
levels, a marker of inﬂammation, than the non-DM group.
To our opinion, this observation seems to reinforce our
hypothesis of a protective role of sRAGE against a further
increase of the inﬂammatory status in DM patients. Anyway,
the reasons of the diﬀerent results are not clear but could deal
with a diﬀerent regulation of sRAGE expression at cellular
level, the duration of disease, and features of patients
included in the study.
In conclusion, in DM CKD-G5D patients, sRAGE
appeared to be a marker of cardiac remodeling. Indeed,
its increase could be a potential protective mechanism
against the increased risk of cardiovascular complications
related to AGEs and inﬂammation. The causal relationship
between sRAGE and cardiovascular risk in these patients
needs to be further conﬁrmed by mechanistic studies.
Also, the evaluation of additional glycated products, the
quantiﬁcation of sRAGE, secreted form of the receptor, and
a comparison between HD and PD could help to improve
the knowledge of the role of glycated pathways in these
patients.
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